Announcements

  • Evidence on Second-line HIV ART Regimens Not Yet Definitive

    By: David McCombs David McCombs , 8 years ago
    Beyond ritonavir-boosted lopinavir plus raltegravir, the evidence base for second-line HIV/AIDS antiretroviral therapy (ART) is “thin,” necessitating more clinical trials, researchers from multiple centers and the World Health Organization say.